Hepatitis B vaccine fails to fully protect against later infection

Thursday, February 14, 2013 by: David Gutierrez, staff writer
Tags: hepatitis B, vaccine, repeat infection

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
The best way to help your body protect itself against Ebola (or any virus or bacteria)
NJ cops bust teenagers shoveling snow without a permit
Russia throws down the gauntlet: energy supply to Europe cut off; petrodollar abandoned as currency war escalates
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak
Chemotherapy kills cancer patients faster than no treatment at all
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
Why flu shots are the greatest medical fraud in history
Governments seize colloidal silver being used to treat Ebola patients, says advocate
Flu vaccine kills 13 in Italy; death toll rises

(NaturalNews) Significant numbers of people who receive the vaccine against the hepatitis B virus (HBV) as infants will already be vulnerable to HBV infection by the time they reach adolescence, according to a study conducted by researchers from Mackay Medical College in New Taipei City, Taiwan and published in the journal Hepatology.

"While infantile HBV vaccination is highly effective, it is not 100 percent and our study examines the long-term success of the HBV vaccine in a high-risk population," lead author Li-Yu Wang said

Public health officials consider HBV a major global health concern, with approximately two billion people infected worldwide plus another 360 million people considered chronic carriers of the hepatitis B surface antigen (HBsAg).

The presence of HBsAg in the body is considered a marker of active HBV infection.

"Chronic HBV is a major health burden that leads to cirrhosis, liver cancer ... and liver failure," Wang said.

The United States has some of the lowest HBV infection levels in the world, with only about 0.5 percent of the population infected. Taiwan, in contrast, has an infection rate of approximately 95 percent, with about 20 percent of the population also classified as HBsAg carriers. As a result, Taiwan became the first country to initiate universal HBV vaccination in the 1980s. Prior studies indicate that the vaccination program was indeed successful in reducing infection and carrier rates among Taiwanese children, as well as reducing cases of severe hepatitis in infants and childhood liver cancer.

Reinfection still possible

The researchers tested 8,733 high school students who had been born between July 1987 and July 1991 for the presence of HBsAg and its antibodies, and also examined their vaccination records. The participants had a mean age of 16 and were all students at schools in Hualien County in eastern Taiwan. 53 percent of study participants were male.

The researchers found that although all the students had been vaccinated against HBV as children, two percent of them tested positive for HBsAg, indicating infection, while 48 percent - nearly half - tested positive for antibodies to HBsAg, indicating an immune reaction to HBV exposure.

HBV is transmitted sexually or via blood transfusions.

The researchers also found that among students who had received both the vaccine and HBV immune globulin (antibodies), the infection rate was even higher, at 15 percent. The numbers were even higher among students who had received the immune globulin on an improper schedule, and among those whose mothers tested positive for HBeAg (another HBV protein that indicates the ability to transmit the disease).

Students who had not received the immune globulin were less likely to test positive for HBsAg the more of the vaccine they had received.

The researchers suggested that a booster vaccine might be needed at around age 15 to restore protection for those vaccinated as infants, especially those born to high-risk mothers or otherwise at high risk of exposure. They also suggested that a routine anti-HBV treatment could be given to pregnant women, although they acknowledged that neither the effectiveness nor safety of such a measure has yet been proven.


Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...


Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of, the internet's No. 1 natural health news site. (Source:

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.